Bio Path Holdings Inc
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in … Read more
Bio Path Holdings Inc (BPTH) - Total Liabilities
Latest total liabilities as of September 2025: $8.70 Million USD
Based on the latest financial reports, Bio Path Holdings Inc (BPTH) has total liabilities worth $8.70 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bio Path Holdings Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how Bio Path Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bio Path Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Bio Path Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Citrus Plant5-L
TA:CTPL5
|
Israel | ILA20.98 Million |
|
Canada One Mining Corp.
PINK:COMCF
|
USA | $1.95 Million |
|
Petrochemical
TA:PTCH
|
Israel | ILA641.07 Million |
|
AMADEUS IT HOLD -A-
BE:AI3A
|
Germany | €6.74 Billion |
|
Wisconsin Electric Power Company PFD 3.60%
OTCQB:WELPP
|
USA | $11.06 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Bio Path Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 12.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bio Path Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bio Path Holdings Inc (2003–2024)
The table below shows the annual total liabilities of Bio Path Holdings Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.73 Million | +34.18% |
| 2023-12-31 | $2.78 Million | +54.65% |
| 2022-12-31 | $1.80 Million | +61.75% |
| 2021-12-31 | $1.11 Million | -20.93% |
| 2020-12-31 | $1.41 Million | -10.74% |
| 2019-12-31 | $1.57 Million | +40.91% |
| 2018-12-31 | $1.12 Million | +41.21% |
| 2017-12-31 | $791.00K | -80.01% |
| 2016-12-31 | $3.96 Million | +322.01% |
| 2015-12-31 | $937.41K | +66.81% |
| 2014-12-31 | $561.97K | +90.56% |
| 2013-12-31 | $294.90K | -10.43% |
| 2012-12-31 | $329.24K | +4.15% |
| 2011-12-31 | $316.13K | +28.11% |
| 2010-12-31 | $246.76K | -6.85% |
| 2009-12-31 | $264.90K | -19.06% |
| 2008-12-31 | $327.29K | +72.65% |
| 2007-12-31 | $189.56K | -18.25% |
| 2006-12-31 | $231.88K | -27.31% |
| 2005-12-31 | $318.98K | 0.00% |
| 2004-12-31 | $318.98K | +31.60% |
| 2003-12-31 | $242.38K | -- |